Sputnik V has been developed by the Gamaleya Research Institute of Epidemiology and Microbiology along with the Russian Direct Investment Fund (RDIF).
The vaccine has not been tested in Phase 3 or larger clinical trials.The Nobel laureate, who is with the Department of Microbiology and Immunology at the Doherty Institute, University of Melbourne, also believes that India with its "great track record in low cost drug manufacturing" can be a major player."Given India’s great track record in low cost drug and vaccine manufacture, we expect that India will be a major player.